Abstract: Melatonin exerts many physiological effects via melatonin receptors, among which the melatonin-2 receptor (MT 2 ) plays a critical role in circadian rhythm disorders, Alzheimer's disease and other neurological disorders. A melatonin replacement strategy has been tested previously, and MT 2 was a critical target during the process. cAMP response element binding (CREB) is an essential transcription factor for memory formation and could be involved in MT 2 signalling. Therefore, the present study was designed to investigate the effects of prophylactic melatonin on inhaled anaesthetic isoflurane-induced cognitive impairment, and to determine whether the protective effects of melatonin are dependent on MT 2 and downstream CREB signalling in the hippocampus of aged rats. The results showed that prophylactic melatonin attenuated isoflurane-induced decreases in plasma/hippocampal melatonin levels and cognitive impairment in aged rats. Furthermore, 4P-PDOT, a selective MT 2 antagonist, blocked the protective effects of melatonin on isoflurane-induced decreases in both hippocampal MT 2 expression and downstream CREB phosphorylation. And 4P-PDOT blocked the attenuation of melatonin on isoflurane-induced memory impairment. Collectively, the results suggest that the protective effects of prophylactic melatonin are dependent on hippocampal MT 2 -CREB signalling, which could be a potential therapeutic target for anaesthetic-induced cognitive impairment.
Melatonin is synthesized primarily in the pineal gland, and its production decreases with age and certain diseases, for example malignancies [1] , Alzheimer's disease (AD) [2] and cardiovascular disease [3] . In addition to antioxidant activity [4] , melatonin exerts many of its physiological actions via G proteincoupled melatonin-1 and melatonin-2 receptor (MT 1 , MT 2 ) subtypes [5] . MT 1 is expressed in various tissues, including those throughout the cardiovascular and immune systems and the brain, but its expression in the hippocampus is relatively low. In contrast, the expression of MT 2 is more restricted primarily to the brain and is enriched in the hippocampus [6] . In ageing and AD patients, MT 1 expression is decreased in the cortex [7] and increased in the hippocampus [8] while MT 2 expression is reduced in the retina, cortex and hippocampus [9] . Furthermore, up-regulation of MT 2 , but not MT 1 , could be a therapeutic target for improving learning, memory and neural stem cell proliferation, and may be beneficial for AD [10] .
Inhaled anaesthetic isoflurane has been widely used in clinical practice, and isoflurane has been reported to induce structural and functional changes within the central nervous system [11] [12] [13] [14] . The underlying mechanisms for this include neuroinflammation and AD-related neurotoxicity [15, 16] . We previously reported that isoflurane exposure affected hippocampal melatonin receptors, which could be stabilized with melatonin pre-treatment [17] . Considering the role of hippocampal MT 2 in AD and related cognitive impairment [10] , we hypothesized that MT 2 signalling may also play a role in isoflurane-induced neurotoxicity and cognitive impairment.
A number of melatonin replacement strategies for circadian rhythm-dependent disorders, AD and other neurological and stressful conditions have been used in which melatonin exerted neuroprotective effects [18] ; these suggest that MT 2 could be an important therapeutic target. Moreover, cAMP response elementbinding protein (CREB) is an essential transcription factor in Ca 2+ / cAMP signalling that activates gene expression for memory formation. The transcriptional activity of CREB is dependent on phosphorylation at serine 133 (S133) [19] , and it has been reported that decreased hippocampal CREB phosphorylation (pCREB) is associated with memory impairment [20] ; hence, we hypothesized that CREB is involved in MT 2 -mediated protective effects of melatonin. Therefore, the present study was designed to investigate the effects of prophylactic melatonin on isoflurane-induced cognitive impairment, and furthermore, to determine whether the protective effects of melatonin are dependent on MT 2 and downstream CREB signalling in the hippocampus of aged rats.
Materials and Methods
and water ad libitum. The study protocol was approved by the Biomedical Ethics Committee, Experimental Animal Ethics Branch, Peking University, Beijing, China (Approval No. LA2010-031).
Study protocol. To study the effects of isoflurane exposure on the MT 2 -CREB signalling pathway, the rats were randomly assigned to isoflurane (n = 30) or control (n = 21) group and exposed to isoflurane (Baxter, Deerfield, IL, USA) or vehicle gas (50% O 2 and 50% air), respectively. Plasma and hippocampal melatonin levels, and hippocampal MT 2 and CREB levels were assessed at 1 and 2 days after isoflurane exposure in the isoflurane group, as well as in the control group by Enzyme-linked immunosorbent assay (ELISA), Western blot and immunofluorescence (n = 6 for ELISA and Western blot, and n = 3 for immunofluorescence per each time-point). Spatial learning and memory function were evaluated with the Morris water maze test 1 day after isoflurane exposure or in control condition (n = 12).
To further evaluate the role of the MT 2 -CREB signalling pathway in isoflurane-induced cognitive impairment, the rats were randomly divided into six groups: Con, Mel, Iso, Iso+Mel, Iso+4P-PDOT and Iso+Mel+4P-PDOT groups (n = 21). Rats in the Iso, Iso+Mel, Iso+4P-PDOT and Iso+Mel+4P-PDOT groups were exposed to isoflurane, and rats in the Con and Mel groups were only exposed to vehicle gas. Rats in the Mel and Iso+Mel groups received intraperitoneal melatonin (Sigma-Aldrich, St. Louis, MO, USA) 10 mg/kg 30 min. before exposure, and rats in the Iso+4P-PDOT group received intraperitoneal 4-phenyl-2-propionamidotetraline (4P-PDOT, a selective MT 2 antagonist; Tocris, Minneapolis, MN, USA) in a dose of 10 mg/kg 40 min. before exposure. Rats in the Iso+Mel+4P-PDOT group received intraperitoneal 10 mg/kg of 4P-PDOT and 10 mg/kg of melatonin at 40 min. and 30 min. before exposure, respectively. Plasma and hippocampal melatonin levels, and hippocampal MT 2 and CREB levels were assessed 1 day after isoflurane exposure in the isoflurane group, as well as in the control group by ELISA, Western blot and in situ hybridization (n = 6 for ELISA and Western blot, and n = 3 for in situ hybridization). Spatial learning and memory function were evaluated with the Morris water maze test 1 day after isoflurane exposure or in control condition (n = 12).
Isoflurane exposure. Isoflurane exposure was performed according to our previous study protocol [16] . Briefly, rats received 2% isoflurane for 4 hr in an anaesthesia chamber, with concentration monitoring from a gas outlet. SaO 2 , heart rate, blood pressure and rectal temperature were monitored, and rats received 100% oxygen after exposure until consciousness was regained. Isoflurane was well tolerated with all monitored variables in the physiological range.
Enzyme-linked immunosorbent assay. An ELISA kit (Elabscience, Wuhan, China) was used to determine plasma and hippocampal melatonin levels, and another ELISA kit (Rapidbio, West Hills, CA, USA) was used to determine hippocampal MT 2 levels. For the detection in hippocampus, rat hippocampus was homogenized and the total protein concentration of each supernatant was determined using bicinchoninic acid (BCA) assay. Melatonin and MT 2 levels were measured according to the manufacturer's instructions.
In situ hybridization. In situ hybridization was performed to determine MT 2 mRNA distribution in the hippocampus. Briefly, rat hippocampus was fixed with 4% paraformaldehyde and cryosectioning was performed using Leica cryostat (Leica, Deerfield, IL, USA). Coronal sections (20 lm thick) were quenched with a methanol/H 2 O 2 mixture, and mRNA nucleic acid fragments were exposed to pepsase. Sections were hybridized with digoxigenin-labelled antisense and sense oligonucleotide probes (5 0 -CATGC CACTG ACTGC AGGCT CGGTG GTAGG-3 0 , 5 0 -CTAGA GACCC CACAA AGAAA TTGGG CACCA-3 0 , 5 0 -TTAGG AAACT GCGCA GGTCA CTGGG TCTCA-3 0 ) and incubated with antidigoxin antibody. Next, the Strept Avidin-Biotin Complex (SABC) method was applied and staining was revealed by DAB reaction. Images were captured with a Nikon Eclipse E600 microscope (Nikon, Tokyo, Japan). Because the CA3 region of the hippocampus plays an important role in the encoding of spatial memory information, as well as cooperation with the CA1 region based on the Schaffer collateral output from CA3 to CA1 [21] , this region was analysed.
Western blot. Western blot was performed to determine pCREB levels in the hippocampus. Briefly, each hippocampus and lysis buffer were homogenized and centrifuged, and the total protein concentration was determined. After electrophoresis of protein lysates on SDS-PAGE, separated proteins were transferred to membranes and nonspecific binding sites were blocked. Subsequently, membranes were incubated with anti-pCREB antibody (1:1000; Abcam, Cambridge, UK) and incubated with fluorescently labelled secondary antibody (1:10,000; LI-COR, Lincoln, NE, USA). Immunoreactivity was visualized by scanning membranes in an Odyssey infrared imaging system (LI-COR).
Immunofluorescence. Immunofluorescence was performed to determine pCREB expression and distribution in the hippocampus as described previously [14] . Briefly, hippocampus was fixed and cryosectioning was performed with cryostat (Leica). Twentymicrometre-thick coronal sections were incubated in pCREB antibody (1:100; Abcam), and in Alexa Fluor â 488-conjugated secondary antibody (1:200; Abcam). Then nuclei were counterstained with DAPI (1:5000; Roche, Mannheim, Germany). Images were captured with Leica TCS SP8 X confocal fluorescence microscopy (Leica Microsystems, Wetzlar, Germany), and the CA3 region of hippocampus was analysed.
Morris water maze. Spatial learning and memory were evaluated by Morris water maze test. Place navigation test was performed 1 day after isoflurane exposure, during which rats received four training trials daily for 5 days. In each trial, rats were randomly placed in water at one of four equally spaced start positions. The time to locate a submerged platform (escape latency, defined by a cut-off time of 120 sec.) and swimming speed were recorded. Probe tests (120 sec.) were performed 24 hr after the last trial, during which the platform was removed and the target quadrant dwell time and target zone transition were recorded. 
Results
Firstly, we observed the effect of isoflurane and melatonin on plasma and hippocampal melatonin levels, as well as cognitive function in aged rats. Compared with controls, plasma and hippocampal melatonin levels were significantly decreased 1 day and 2 days after isoflurane exposure (p < 0.001 and p < 0.05, respectively, fig. 1A,B) . Prophylactic melatonin attenuated isoflurane-induced decrease in plasma and hippocampal melatonin levels (p < 0.001 and p < 0.01, respectively), but melatonin alone did not affect plasma or hippocampal melatonin levels (p > 0.05, fig. 1C,D) . The
Morris water maze navigation task shows that both group factor and repeated factor (day) significantly affected escape latency (p < 0.001), but no interaction was found (p > 0.05). The Bonferroni test shows that compared with controls, isoflurane prolonged escape latency on days 3-5 after exposure (p < 0.05), and melatonin attenuated isoflurane-induced prolonged escape latency (p < 0.05), but melatonin alone did not affect escape latency (p > 0.05, fig. 1E ). There was no significant difference in swimming speed between the groups (p > 0.05, fig. 1F ). In the probe test, compared with controls, target quadrant dwell time and target zone transition were significantly decreased after isoflurane exposure (p < 0.05), and melatonin attenuated the isoflurane-induced decrease in target quadrant dwell time and target zone transition (p < 0.05 and p < 0.01), but melatonin alone did not affect them (p > 0.05, fig. 1G,H) . These results indicate that prophylactic melatonin could be an effective therapeutic intervention for isofluraneinduced cognitive impairment.
As mentioned above, MT 2 is enriched in the hippocampus, and is involved in modulating synaptic plasticity and cognitive function. Moreover, hippocampal MT 2 expression is decreased in the AD model [10] . Therefore, we observed the effect of isoflurane, as well as prophylactic melatonin and 4P-PDOT on MT 2 receptor expression in the hippocampus of aged rats. The results show that compared with controls, hippocampal MT 2 expression decreased significantly 1 day and 2 days after isoflurane exposure (p < 0.001, fig. 2A ), and prophylactic melatonin attenuated the decrease in hippocampal MT 2 expression 1 day after isoflurane exposure (p < 0.001), but melatonin alone did not affect hippocampal MT 2 expression (p > 0.05, fig. 2B ). When we applied pre-treatment with 4P-PDOT, the attenuation of melatonin on isoflurane-induced decrease in hippocampal MT 2 expression was blocked (p > 0.05, fig. 2C ). Additionally, MT 2 mRNA distribution in the pyramidal cell layer, CA3 region of the hippocampus was observed with in situ hybridization. The results indicate that MT 2 mRNA distribution decreased 1 day after isoflurane exposure, and melatonin attenuated this effect, but melatonin alone did not affect MT 2 mRNA distribution. With 4P-PDOT pre-treatment, melatonin no longer attenuated the decrease in hippocampal MT 2 mRNA distribution after isoflurane fig. 2D) , which was consistent with the MT 2 expression results detected by ELISA.
cAMP response element-binding phosphorylation is involved in memory formation and plays an important role in cognitive impairment [19, 22] , and the melatonin agonist has been reported to decrease pCREB in pancreatic cells [23] . However, the effect of MT 2 on pCREB in the hippocampus, and the role of MT 2 -CREB signalling pathway in isofluraneinduced cognitive impairment remained unclear, so we observed the effect of isoflurane, as well as prophylactic melatonin and 4P-PDOT on pCREB. The Western blot results show that hippocampal pCREB (S133) was significantly decreased 1 day and 2 days after isoflurane exposure (p < 0.001 and p < 0.01, fig. 3A,B) , and the immunofluorescence results show that compared with control condition, pCREB level in the pyramidal cell layer, CA3 region of the hippocampus decreased 1 day and 2 days after isoflurane exposure ( fig. 3C) , which was consistent with Western blot results. Moreover, prophylactic melatonin attenuated the decrease in hippocampal pCREB 1 day after isoflurane exposure (p < 0.001), but melatonin alone did not affect it (p > 0.05, fig. 3D,E) . With 4P-PDOT pre-treatment, melatonin no longer attenuated the decrease in hippocampal pCREB after isoflurane exposure (p > 0.05, fig. 3D,F) . Furthermore, the Morris water maze navigation task results showed that both group factor and repeated factor significantly affected escape latency (p < 0.001), but no interaction was found (p > 0.05). The Bonferroni test shows that melatonin attenuated isoflurane-induced prolonged escape latency in control condition (p < 0.05), but not with 4P-PDOT pretreatment (p > 0.05, fig. 4A ). There was no significant difference in swimming speed between the groups (p > 0.05, fig. 4B ). In the probe test, melatonin also attenuated isoflurane-induced decrease in target quadrant dwell time and target zone transition in control condition (p < 0.05 or p < 0.01), but not with 4P-PDOT pre-treatment (p > 0.05, fig. 4C,D) . Thus, the present results indicate that prophylactic melatonin attenuates isoflurane-induced cognitive impairment, and its effects are dependent on hippocampal MT 2 -CREB signalling pathway.
Discussion
General anaesthesia is an altered state of consciousness [24] and has an impact on the circadian timing system [25] . Older individuals have melatonin deficiency [26] and are more vulnerable to anaesthesia-related circadian rhythm disturbances. We previously reported that an inhaled anaesthetic could impair melatonin secretion and further affect cognitive function [17] . Therefore, we applied melatonin as a therapeutic intervention for anaesthesia-related decrease in melatonin, and the results indicated that both two consecutive weeks of supplements [17] and supplements immediately before anaesthesia provided protective effects for plasma and hippocampal melatonin stabilization, as well as cognitive improvement after anaesthetic exposure.
Melatonin exerts neuroprotective effects including antioxidation and anti-inflammation [27] , and theoretically, these effects are exerted via activation of MT 1 and MT 2 receptors [5] . Melatonin receptors are localized in the dentate gyrus and the CA3 and CA1 regions of the hippocampus [28] . Long-duration melatonin treatments were effective in reducing the magnitude of long-term potentiation, which could be blocked by MT 2 antagonists. And the inhibitory effects of melatonin were lost in MT 2 -deficient, but not MT 1 -deficient mice [29] . In MT 2 knockout mice, hippocampal long-term synaptic plasticity, learning ability and memory were impaired [30] , and overexpression of melatonin receptors increased calcium-binding proteins and protected against neurotoxicity through multiple mechanisms [31] .
Our previous study showed that an inhaled anaesthetic increased MT 1 and decreased MT 2 in the hippocampus of aged rats [17] . We speculate that higher MT 1 levels reflect the adaptation of hippocampal neurons to inhaled anaestheticinduced decrease in melatonin, and the decrease in MT 2 could be the upstream mechanism for inhaled anaesthetic-induced cognitive impairment. Thus, a MT 2 antagonist was applied in the present study, and the results showed that the MT 2 antagonist blocked the protective effects of melatonin, which indicate that hippocampal MT 2 plays a critical role in the neuroprotective effects of melatonin on anaesthetic-induced cognitive impairment in aged rats.
Melatonin modulates the efficiency of hippocampal glutamatergic synapses through MT 2 in the hippocampus [32] . In AD patients, MT 2 distribution decreases in the hippocampus, cortex and retina [9] , and MT 2 À/À mice express a similar phenotype as AD models, including long-term potentiation maintenance and learning/memory impairment [30] . The present results indicate that the decrease in hippocampal MT 2 is also involved in inhaled anaesthetic-induced cognitive impairment. Then, we explored possible downstream mechanisms and found that decreases in MT 2 lead to decrease in pCREB in the hippocampus. CREB has been reported to be involved in cued and contextual fear memory, spatial memory, olfactory memory, object and social recognition memory and others [33] . CREB also plays a critical role in central nervous system development, and CREB null mice were shown to die immediately after birth and exhibited marked defects in central nervous system development [34] . Furthermore, CREB regulates reactive oxygen species through stimulation of antioxidant gene expression [35] and plays a critical role in preconditioning-evoked neuroprotective effects [36] . CREB dysregulation is implicated in multiple congenital and acquired brain diseases including AD, Parkinson's disease, Huntington's disease and alcoholism [37, 38] . Therefore, MT 2 -CREB signalling pathway could play a critical role in anaesthetic-induced cognitive impairment. Furthermore, MT 2 has been shown to activate ERK1/2 and PI3K/AKT signalling [39] , but a full picture of downstream signalling is lacking and needs further investigation. MT 2 receptor is also involved in neurological diseases including circadian rhythm disorders [40] , anxiety [41] , depression [42] , Parkinson disease [43] , adolescent idiopathic scoliosis [44] and ischaemic neuronal damage [45] . Therefore, MT 2 -CREB signalling pathway could be a valuable therapeutic target not just for anaesthetic-induced cognitive impairment, but also for multiple neurological disorders.
In conclusion, the present study showed that prophylactic melatonin attenuated the decrease in isoflurane-induced plasma/hippocampal melatonin and cognitive impairment in aged rats. Furthermore, 4P-PDOT, a selective MT 2 antagonist, blocked the protective effects of melatonin on isofluraneinduced decreases in both hippocampal MT 2 expression and downstream pCREB. And 4P-PDOT blocked the attenuation of melatonin on isoflurane-induced memory impairment. Collectively, these results suggest that the protective effect of prophylactic melatonin is dependent on hippocampal MT 2 -CREB signalling, which could be a potential therapeutic target for anaesthetic-induced cognitive impairment.
